ESC 365 - Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients

ESC Premium Access

Selatogrel, a novel P2Y12 inhibitor for emergency use, achieves rapid, consistent and sustained platelet inhibition following single-dose subcutaneous administration in stable CAD patients

Session: New developments in anti thrombotic drug therapy

Topic: Antiplatelet Drugs

Speaker: Professor R. Storey (Sheffield, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Professor Robert Storey

University of Sheffield, Sheffield (United Kingdom of Great Britain & Northern Ireland)

24 presentations

1 follower

3 more presentations in this session

State of the Art - Novel targets in anti thrombotic drug development

Speaker: Professor B. Rocca (Casamassima, IT)

Novel direct thrombin inhibitor achieves superior antithrombotic effect with lower bleeding risk than heparin or bivalirudin

Speaker: Assistant Professor C. Koh (Singapore, SG)

Evaluation of the pharmacodynamics of a ticagrelor reversal agent PB2452

Speaker: Professor L. Jennings (Memphis, US)

Access the full session

New developments in anti thrombotic drug therapy

Speakers: Professor R. Storey, Professor B. Rocca, Assistant Professor C. Koh, Professor L. Jennings

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources